CA2431990A1 - Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes - Google Patents

Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes Download PDF

Info

Publication number
CA2431990A1
CA2431990A1 CA002431990A CA2431990A CA2431990A1 CA 2431990 A1 CA2431990 A1 CA 2431990A1 CA 002431990 A CA002431990 A CA 002431990A CA 2431990 A CA2431990 A CA 2431990A CA 2431990 A1 CA2431990 A1 CA 2431990A1
Authority
CA
Canada
Prior art keywords
cells
sign
cell
endothelial layer
lsec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002431990A
Other languages
English (en)
French (fr)
Inventor
Carl Gustav Figdor
Teunis Bernard Herman Geijtenbeek
Yvette Van Kooyk
Ruurd Torensma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2431990A1 publication Critical patent/CA2431990A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CA002431990A 2000-12-21 2001-12-21 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes Abandoned CA2431990A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00128143.5 2000-12-21
EP00128143 2000-12-21
EP01200944 2001-03-13
EP01200944.5 2001-03-13
PCT/EP2001/015392 WO2002050119A2 (en) 2000-12-21 2001-12-21 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes

Publications (1)

Publication Number Publication Date
CA2431990A1 true CA2431990A1 (en) 2002-06-27

Family

ID=26071682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002431990A Abandoned CA2431990A1 (en) 2000-12-21 2001-12-21 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes

Country Status (6)

Country Link
US (2) US20040091481A1 (enExample)
EP (1) EP1339830A2 (enExample)
JP (3) JP4322504B2 (enExample)
AU (2) AU3329902A (enExample)
CA (1) CA2431990A1 (enExample)
WO (1) WO2002050119A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
EP1339830A2 (en) * 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2004026326A2 (en) * 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
NZ542134A (en) * 2003-03-04 2009-06-26 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US20050281828A1 (en) * 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
AU2011211337B2 (en) * 2003-10-16 2014-10-02 Cancure Limited Immunomodulating compositions and uses therefor
WO2005100601A2 (en) * 2004-03-26 2005-10-27 Progenics Pharmaceuticals, Inc. L-sign polymorphisms and methods involving use of same
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
CN108210503A (zh) * 2016-12-10 2018-06-29 高尚先 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途
CN112402440A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备治疗血窦内皮细胞病理性功能异常相关产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
EP1339830A2 (en) * 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US7022323B2 (en) * 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US20030013081A1 (en) * 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers

Also Published As

Publication number Publication date
JP2005132846A (ja) 2005-05-26
WO2002050119A3 (en) 2002-09-19
JP2009108092A (ja) 2009-05-21
AU3329902A (en) 2002-07-01
US20070134693A1 (en) 2007-06-14
US20040091481A1 (en) 2004-05-13
JP2004526685A (ja) 2004-09-02
JP4322504B2 (ja) 2009-09-02
AU2002233299B2 (en) 2006-07-20
WO2002050119A2 (en) 2002-06-27
EP1339830A2 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
Bashirova et al. A dendritic cell–specific intercellular adhesion molecule 3–grabbing nonintegrin (DC-SIGN)–related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection
JP2009108092A (ja) 肝臓およびリンパ節中の類洞内皮細胞上において、新規なｉｃａｍ−３結合レセプターの結合活性を調節するための方法
KR101600225B1 (ko) 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
WO2018223601A1 (zh) 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
US6620922B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2018218877A1 (zh) 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
KR20230150813A (ko) 치료 및 진단 제제와 이의 용도
JP2024544903A (ja) Ｈｐｖ１６ ｅ７抗原を認識する結合タンパク質及びその使用
US20220152104A1 (en) T cell receptors and methods of use thereof
US20200206308A1 (en) Suppression of allergic lung inflammation and hyperreactivity
US6630305B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US6548295B2 (en) Complex of lipo-viro-particles, method of preparation and applications
US6894146B1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CN102257002B (zh) 截短CD20蛋白质,DeltaCD20
AU776955B2 (en) Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
CN1844147A (zh) 抗人cd154单克隆抗体及其应用
JPWO2023086477A5 (enExample)
JP4470146B2 (ja) 軟骨型フィブロネクチンの検出方法、該方法を用いる軟骨腫瘍検出方法、抗軟骨型ｆｎモノクローナル抗体、及び該抗体を産生するハイブリドーマ
WO2024192134A1 (en) Bispecific cars for the treatment of lupus and autoimmune diseases
US20060024301A1 (en) Prostate-specific polypeptides and fusion polypeptides thereof
Hedrick Characterization of a novel receptor for the Epstein-Barr virus

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20101221